Endoprostheses containing boride intermetallic phases

• US 7,604,662 B2
• Filed: 07/13/2007
• Issued: 10/20/2009
• Est. Priority Date: 07/13/2007
• Status: Active Grant

• Current Assignee: Boston Scientific Scimed (Boston Scientific Corporation)
• Original Assignee: Boston Scientific Scimed (Boston Scientific Corporation)
• Inventors: Stinson, Jonathan S., O'Brien, Barry, Cambronne, Matthew
• Primary Examiner(s): GHERBI, SUZETTE JAIME J
• Application Number:
  US11/777,674
• Publication Number:
  US 20090018645A1
• Time in Patent Office: 830 Days
• Field of Search: 623 142- 148, 428/433, 427 221- 225
• US Class Current: 623/1.46
• CPC Class Codes: A61L 31/022 Metals or alloys
• CPC Class Codes: A61L 31/128 containing other specific inorganic fillers not covered by A61L31/126 or A61L31/127
• CPC Class Codes: A61L 31/14 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 31/18 Materials at least partially X-ray or laser opaque

Abstract

An endoprosthesis including an alloy having a matrix comprising titanium, niobium, or a combination thereof and a plurality of boride intermetallic phases within the matrix.

Claims

1. An endoprosthesis comprising an alloy that includes

(a) a matrix microstructure comprising titanium, niobium, or a combination thereof;

and

(b) at least one boride intermetallic phase within the matrix, wherein the alloy comprises at least 0.1 weight percent boron.

2. The endoprosthesis of claim 1, wherein the alloy comprises at least 50 weight percent titanium, niobium, or a combination thereof.

3. The endoprosthesis of claim 1, wherein the alloy consists essentially of titanium.

4. The endoprosthesis of claim 1, wherein the alloy consists essentially of niobium.

5. The endoprosthesis of claim 1, wherein the at least one boride intermetallic phase comprises boride intermetallics of a metal selected from the group consisting of titanium, niobium, tantalum, tungsten, zirconium, molybdenum, iridium, and combinations thereof.

6. The endoprosthesis of claim 1, wherein the at least one boride intermetallic phase comprises titanium boride.

7. The endoprosthesis of claim 1, further comprising a plurality of boride intermetallic phases within the matrix.

8. The endoprosthesis of claim 7, wherein the plurality of boride intermetallic phases have an average length, width, or diameter of between 10 nanometers and 50 microns.

9. The endoprosthesis of claim 8, wherein the average length, width, or diameter of the boride intermetallic phases is between 1 micron and 40 microns.

10. The endoprosthesis of claim 1, wherein the alloy comprises up to 1.5 weight percent boron.

11. The endoprosthesis of claim 1, wherein the alloy comprises at least 50 weight percent niobium and the plurality of boride intermetallic phases comprise at least 50 weight percent titanium boride.

12. The endoprosthesis of claim 1, wherein the alloy comprises up to 0.200 weight percent oxygen.

13. The endoprosthesis of claim 1, further comprising a radiopaque material.

14. The endoprosthesis of claim 13, comprising an outer layer comprising the radiopaque material.

15. The endoprosthesis of claim 13, wherein the matrix comprises the radiopaque material.

16. The endoprosthesis of claim 15, wherein the matrix comprises between 30 to 50 weight percent of the radiopaque material.

17. The endoprosthesis of claim 13, wherein the radiopaque material comprises tantalum, iridium, or a combination thereof.

18. The endoprosthesis of claim 1, further comprising a surface layer comprising an oxide of titanium, an oxide of niobium, or a combination thereof.

19. The endoprosthesis of claim 1, wherein the endoprosthesis is a stent.

20. The endoprosthesis of claim 19, wherein the stent is a balloon-expandable stent.

21. The endoprosthesis of claim 19, wherein the stent comprises a wall thickness of between 0.0015 and 0.0060 inches.

22. The endoprosthesis of claim 19, wherein the stent comprises diameter recoil of less than 8 percent upon balloon expansion to 3.2 mm diameter.

23. The endoprosthesis of claim 19, wherein the stent requires 0.10 to 0.50 Newtons force per millimeter of stent length to compress it from an initial balloon expanded diameter of 3.2 mm to 2.75 mm diameter within a V-shaped platens compression tester.

25. The endoprosthesis of claim 1, wherein the alloy further comprises a metal selected from the group consisting of aluminum, vanadium, zirconium, tantalum, molybdenum, iridium, and combinations thereof.

28. The endoprosthesis of claim 1, further comprising an oxide, nitride, carbide, or combination thereof of the matrix on the surface of the finished part.

29. The endoprosthesis of claim 1, wherein the alloy has a Young'"'"'s modulus of between 14 and 25 msi.

31. The endoprosthesis of claim 1, wherein the alloy has a percent elongation at fracture of between 5 percent to 30 percent.

32. The endoprosthesis of claim 1, wherein the alloy overlies a base comprising stainless steel, platinum enhanced stainless steel, nitinol, or Co—

Cr alloy.

24. An endoprosthesis comprising an alloy that includes

(a) a matrix microstructure comprising titanium, niobium, or a combination thereof, wherein the alloy comprises at least 65 weight percent niobium;

and

(b) at least one boride intermetallic phase within the matrix.

26. An endoprosthesis comprising an alloy that includes

(a) a matrix microstructure comprising titanium, niobium, or a combination thereof;

and

(b) at least one boride intermetallic phase within the matrix, wherein boride intermetallic phases protrude from a surface of the alloy to create a micro-textured surface.

27. The endoprosthesis of claim 26, further comprising a drug-eluting polymer coating on the micro-textured surface.

30. An endoprosthesis comprising an alloy that includes

(a) a matrix microstructure comprising titanium, niobium, or a combination thereof;

and

(b) at least one boride intermetallic phase within the matrix, wherein the alloy has a 0.2% offset yield strength of between 50 and 110 ksi.